ID   NPC-TY861
AC   CVCL_A5WW
SY   TY861
DR   Wikidata; Q107116579
RX   DOI=10.11334/jibi1954.34.1Supplement1_329;
RX   PubMed=1902254;
CC   Doubling time: 18 hours (DOI=10.11334/jibi1954.34.1Supplement1_329).
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
CC   Derived from site: In situ; Pharynx, nasopharynx; UBERON=UBERON_0001728.
DI   NCIt; C3871; Nasopharyngeal carcinoma
DI   ORDO; Orphanet_150; Nasopharyngeal carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 20-05-21; Last updated: 29-06-23; Version: 4
//
RX   DOI=10.11334/jibi1954.34.1Supplement1_329;
RA   Yanoma, Shunsuke
RA   Tsukuda, Mamoru
RA   Sawaki, Shuji
RT   "Establishment and characterization of nasopharyngeal carcinoma cell
RT   line.";
RL   Jibi To Rinsho 34 Suppl. 1:329-333(1988).
//
RX   PubMed=1902254; DOI=10.3950/jibiinkoka.94.28;
RA   Tsukuda, Mamoru
RA   Kubota, Akira
RA   Kaneko, Madoka
RA   Yoshida, Toyokazu
RA   Sawaki, Shuji
RT   "The characteristics of nasopharyngeal carcinoma cell strain against
RT   chemotherapeutic agents and cytokines.";
RL   Nihon Jibiinkoka Gakkai Kaiho 94:28-33(1991).
//